The clinical efficacy of BAY o 9867, a new quinoline carboxylic acid derivative, was studied in dermatological infectious diseases. BAY o 9867 was administered to 33 patients with various skin infectious diseases. The dose was 300~600mg and the duration of administration was 3 to 17 days. The isolated organisms from affected sites were S. aureus, S. epidermidis, P. acnes, S. capitis, Peptostreptococcus, P. avidum, S. pyogenes, S. xylosus. S. aureus and S. epidermidis were all eliminated. Clinical results were excellent in 8 cases, good in 21cases, fair in 2 cases and poor in 2 cases. The overall efficacy rate was 87.9%. As the side effect of BAY o 9867, mild heartburn was noted in 1 case. As the abnormal changes in laboratory data, slight increase of BUN was found in only 1 case.
|Number of pages||5|
|Publication status||Published - Jan 1 1985|
All Science Journal Classification (ASJC) codes
- Pharmacology (medical)
- Infectious Diseases
- Drug Discovery